Financial HealthCOMPASS ended the quarter with $221.9 million in cash, extending its runway into 2027 and enabling continued investment in TRD, PTSD, and commercial readiness.
Market PositionCOMPASS is at the forefront of the psychedelic medicine space as the only company with statistically significant Phase 3 data in hand for a classical psychedelic.
Regulatory ProgressThe Phase 3 COMP005 trial met its primary endpoint with a statistically significant and clinically meaningful separation on the Montgomery–Åsberg Depression Rating Scale (MADRS) at Week 6 after a single 25 mg dose, establishing a credible safety and efficacy foundation for regulatory review.